Effectiveness and Safety of a Mixture of Nobiletin and Tangeretin in Nocturia Patients: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study

被引:5
|
作者
Ito, Haruki [1 ]
Negoro, Hiromitsu [2 ]
Kono, Jin [3 ]
Hayata, Naoki [1 ]
Miura, Takayoshi [1 ]
Manabe, Yumi [1 ]
Miyazaki, Yu [1 ]
Mishina, Mutsuki [1 ]
Woo, Je Tae [4 ]
Sakane, Naoki [5 ]
Okuno, Hiroshi [1 ]
机构
[1] Natl Hosp Org, Kyoto Med Ctr, Dept Urol, Kyoto 6128555, Japan
[2] Univ Tsukuba, Inst Med, Dept Urol, Tsukuba 3058575, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto 6068507, Japan
[4] Chubu Univ, Coll Biosci & Biotechnol, Dept Biol Chem, Kasugai 4878501, Japan
[5] Natl Hosp Org, Clin Res Inst, Kyoto Med Ctr, Div Prevent Med, Kyoto 6128555, Japan
关键词
clinical trial; flavonoid; voiding diary; URINARY-TRACT SYMPTOMS; NETWORK; MEN;
D O I
10.3390/jcm12082757
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nobiletin and tangeretin (NoT) are flavonoids derived from the peel of Citrus depressa, and they have been found to modulate circadian rhythms. Because nocturia can be considered a circadian rhythm disorder, we investigated the efficacy of NoT for treating nocturia. A randomized, placebo-controlled, double-blind, crossover study was conducted. The trial was registered with the Japan Registry of Clinical Trials (jRCTs051180071). Nocturia patients aged >= 50 years who presented nocturia more than 2 times on a frequency-volume chart were recruited. Participants received NoT or a placebo (50 mg once daily for 6 weeks), followed by a washout period of >= 2 weeks. The placebo and NoT conditions were then switched. Changes in nocturnal bladder capacity (NBC) were the primary endpoint, and changes in nighttime frequency and nocturnal polyuria index (NPi) were secondary endpoints. Forty patients (13 women) with an average age of 73.5 years were recruited for the study. Thirty-six completed the study, while four withdrew. No adverse events directly related to NoT were observed. NoT had little effect on NBC compared with the placebo. In contrast, NoT significantly changed nighttime frequency by -0.5 voids compared with the placebo (p = 0.040). The change in NPi from baseline to the end of NoT was significant (-2.8%, p = 0.048). In conclusion, NoT showed little change in NBC but resulted in decreased nighttime frequency with a tendency toward reduced NPi.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] A double-blind, placebo-controlled study of the effectiveness and safety of nizatidine in the prevention of postprandial heartburn
    Spiegel, JE
    Thoden, WR
    Pappas, K
    Fratarcangelo, P
    Furey, SA
    ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (14) : 1594 - 1599
  • [42] Effect of Photobiomodulation on Critical Swimming Velocity: A Randomized, Crossover, Double-Blind, and Placebo-Controlled Study
    Teixeira, Cesar L.
    Mezzaroba, Paulo, V
    Machado, Fabiana A.
    INTERNATIONAL JOURNAL OF SPORTS PHYSIOLOGY AND PERFORMANCE, 2021, 16 (07) : 1035 - 1042
  • [43] SERTRALINE FOR SOCIAL PHOBIA - A DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER STUDY
    KATZELNICK, DJ
    KOBAK, KA
    GREIST, JH
    JEFFERSON, JW
    MANTLE, JM
    SERLIN, RC
    AMERICAN JOURNAL OF PSYCHIATRY, 1995, 152 (09): : 1368 - 1371
  • [44] Effects of SuperUlam on Supporting Concentration and Mood: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
    Udani, Jay K.
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 2013
  • [45] Effects of fenofibrate on albuminuria in patients with hypertriglyceridemia and/or hyperuricemia: A multicenter, randomized, double-blind, placebo-controlled, crossover study
    Kazumi, T
    Hirano, T
    Yoshino, G
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2003, 64 (07): : 434 - 446
  • [46] Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: A randomized, double-blind, placebo-controlled crossover study
    Libov, Igor
    Miodownik, Chanoch
    Bersudsky, Yuly
    Dwolatzky, Tzvi
    Lerner, Vladimir
    JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (07) : 1031 - 1037
  • [47] Amitriptyline in neuropathic cancer pain in patients on morphine therapy: A randomized placebo-controlled, double-blind crossover study
    Mercadante, S
    Arcuri, E
    Tirelli, W
    Villari, P
    Casuccio, A
    TUMORI, 2002, 88 (03) : 239 - 242
  • [48] Effectiveness and safety of 0.5% timolol solution in the treatment of pyogenic granuloma: A randomized, double-blind and placebo-controlled study
    Patra, Aparesh Chandra
    Sil, Amrita
    Ahmed, Sk Shahriar
    Rahaman, Sufiur
    Mondal, Nasiruddin
    Roy, Sudipta
    Datta, Adrija
    Kaliyadan, Feroze
    Panda, Saumya
    Setia, Maninder Singh
    Dogra, Sunil
    Khandpur, Sujay
    Hazra, Avijit
    Das, Nilay Kanti
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2022, 88 (04): : 500 - 508
  • [49] Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study
    Cheng, Jocelyn Y.
    Moline, Margaret
    Zammit, Gary K.
    Filippov, Gleb
    Bsharat, Mohammad
    Hall, Nancy
    CLINICAL DRUG INVESTIGATION, 2021, 41 (05) : 449 - 457
  • [50] The role of afferent input in postamputation pain: a randomized, double-blind, placebo-controlled crossover study
    Buch, Nina Stockfleth
    Ahlburg, Peter
    Haroutounian, Simon
    Andersen, Niels Trolle
    Finnerup, Nanna Brix
    Nikolajsen, Lone
    PAIN, 2019, 160 (07) : 1622 - 1633